DK173940B1 - Ligander og fremgangsmåder til forøgelse af B-celle-proliferation samt B-celle-overfladeantigen Bp50 - Google Patents

Ligander og fremgangsmåder til forøgelse af B-celle-proliferation samt B-celle-overfladeantigen Bp50 Download PDF

Info

Publication number
DK173940B1
DK173940B1 DK198703022A DK302287A DK173940B1 DK 173940 B1 DK173940 B1 DK 173940B1 DK 198703022 A DK198703022 A DK 198703022A DK 302287 A DK302287 A DK 302287A DK 173940 B1 DK173940 B1 DK 173940B1
Authority
DK
Denmark
Prior art keywords
cells
cell
bcgf
proliferation
ligand
Prior art date
Application number
DK198703022A
Other languages
Danish (da)
English (en)
Other versions
DK302287A (da
DK302287D0 (da
Inventor
Jeffrey A Ledbetter
Edward A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of DK302287D0 publication Critical patent/DK302287D0/da
Publication of DK302287A publication Critical patent/DK302287A/da
Application granted granted Critical
Publication of DK173940B1 publication Critical patent/DK173940B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198703022A 1986-06-13 1987-06-12 Ligander og fremgangsmåder til forøgelse af B-celle-proliferation samt B-celle-overfladeantigen Bp50 DK173940B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13
US87388486 1986-06-13

Publications (3)

Publication Number Publication Date
DK302287D0 DK302287D0 (da) 1987-06-12
DK302287A DK302287A (da) 1987-12-14
DK173940B1 true DK173940B1 (da) 2002-03-04

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198703022A DK173940B1 (da) 1986-06-13 1987-06-12 Ligander og fremgangsmåder til forøgelse af B-celle-proliferation samt B-celle-overfladeantigen Bp50

Country Status (22)

Country Link
JP (1) JPH0762040B2 (fr)
KR (1) KR910004100B1 (fr)
AT (1) AT398437B (fr)
AU (1) AU617087B2 (fr)
BE (1) BE1000587A4 (fr)
CA (1) CA1338781C (fr)
CH (1) CH676600A5 (fr)
CY (1) CY1681A (fr)
DE (1) DE3719398C2 (fr)
DK (1) DK173940B1 (fr)
FR (1) FR2607136B1 (fr)
GB (1) GB2191494B (fr)
GR (1) GR870930B (fr)
HK (1) HK10293A (fr)
IE (1) IE60486B1 (fr)
IL (1) IL82841A (fr)
IT (1) IT1208649B (fr)
LU (1) LU86919A1 (fr)
NL (1) NL195022C (fr)
PT (1) PT85073B (fr)
SE (1) SE504675C2 (fr)
SG (1) SG118992G (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (fr) * 1983-02-24 1985-09-25 The Regents Of The University Of California Anticorps monoclonal spécifique des monocytes et des cellules blastiques
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
DE3719398A1 (de) 1988-01-28
GB2191494A (en) 1987-12-16
IL82841A0 (en) 1987-12-20
LU86919A1 (fr) 1989-03-08
DK302287A (da) 1987-12-14
HK10293A (en) 1993-02-19
KR880000582A (ko) 1988-03-28
AU7421487A (en) 1987-12-17
NL195022C (nl) 2003-06-18
SE504675C2 (sv) 1997-04-07
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
FR2607136A1 (fr) 1988-05-27
GB2191494B (en) 1990-08-22
SE8702463L (sv) 1987-12-14
PT85073A (en) 1987-07-01
SG118992G (en) 1993-01-29
CA1338781C (fr) 1996-12-10
IL82841A (en) 1992-11-15
AT398437B (de) 1994-12-27
IT8720899A0 (it) 1987-06-12
PT85073B (pt) 1990-07-31
GB8713650D0 (en) 1987-07-15
IE871563L (en) 1987-12-13
JPH0762040B2 (ja) 1995-07-05
GR870930B (en) 1987-12-16
SE8702463D0 (sv) 1987-06-12
AU617087B2 (en) 1991-11-21
IE60486B1 (en) 1994-07-27
BE1000587A4 (fr) 1989-02-14
CH676600A5 (fr) 1991-02-15
FR2607136B1 (fr) 1989-09-15
NL8701371A (nl) 1988-01-04
ATA151387A (de) 1994-04-15
DE3719398C2 (de) 1996-03-28
JPS6480299A (en) 1989-03-27
KR910004100B1 (ko) 1991-06-22
IT1208649B (it) 1989-07-10

Similar Documents

Publication Publication Date Title
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
US5786456A (en) Bp 50-specific antibodies and fragments thereof
Clark et al. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.
Fleischer A novel pathway of human T cell activation via a 103 kD T cell activation antigen.
Burns et al. TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors.
US6641809B1 (en) Method of regulating cellular processes mediated by B7 and CD28
Lanzavecchia et al. Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets.
CA2086325C (fr) Ligand pour le recepteur cd28 sur les cellules b et methodes
Gollob et al. CD2 regulates responsiveness of activated T cells to interleukin 12.
US6569997B1 (en) Antibody specific for H4-1BB
US7445781B2 (en) Anti-CD40CR MR1 antibody
Baroja et al. The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens
ES2249759T3 (es) Anticuerpos monoclonales y fv especificos para antigeno cd2.
Funakoshi et al. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas
Gangemi et al. Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes.
KR20170134331A (ko) 조작된 면역 세포들의 분류/소모를 위한 mAb-주도의 키메라 항원 수용체 시스템들
US6830937B1 (en) Method for generating and identifying antibodies directed against a B7
US20030219446A1 (en) Ligand for CD28 receptor on B cells and methods
Klingbeil et al. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use
DK173940B1 (da) Ligander og fremgangsmåder til forøgelse af B-celle-proliferation samt B-celle-overfladeantigen Bp50
EP0325489B1 (fr) Leu 23: anticorps monoclonal pour monitoring d'activation de leucocytes
Hansson et al. MHC nonrestricted cytotoxic T cell clones with selective specificity from patients with transitional cell carcinoma (TCC) of the urinary bladder
AT400956B (de) Verfahren zur gewinnung eines liganden und verfahren zur unterdrückung der proliferation von bp50 exprimierenden zellen
Lwin et al. Down-regulation of T-cell proliferation in response to soluble anti-CD3 antibodies through development of redirected cytolytic activity eliminating costimulatory cells
Ritz CD2 Regulates Responsiveness of Activated T Cells to Interleukin 12 By Jared A. Gollob,* Jing Li,* Ellis L. Reinherz, r

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired